Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
ValiRx plc ( (GB:VAL) ) has provided an announcement.
ValiRx plc has announced the posting of a circular regarding a General Meeting scheduled for 30 December 2024, following their fundraising announcement. This meeting will address the necessary resolutions for the Admission, Placing, Broker Offer, and Subscription, which are crucial for the company’s capital raise and strategic growth initiatives. The outcomes of the General Meeting and subsequent steps are expected to impact the company’s operations and market positioning significantly.
More about ValiRx plc
ValiRx plc is a life science company specializing in early-stage cancer therapeutics and women’s health. The company focuses on accelerating the translation of innovative science into impactful medicines to improve patient lives. ValiRx provides a supportive framework for the rapid development of novel drug candidates, guiding them from pre-clinical studies to clinic and investor-ready assets.
YTD Price Performance: -86.86%
Average Trading Volume: 1,183,396
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.03M
See more insights into VAL stock on TipRanks’ Stock Analysis page.
